Delving into the Latest Updates on MK-3866 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

MK 3866

Target

β-lactamase

Action

inhibitors

Mechanism

β-lactamase inhibitors(Beta Lactamase inhibitors)

Therapeutic Areas

Urogenital Diseases

Active Indication-

Inactive Indication

Kidney Failure, Chronic

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization-

Inactive Organization

Merck Sharp & Dohme Corp.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

This is an open-label, single-dose, Phase 1 study to evaluate the pharmacokinetics (PK) of intravenous (IV) MK-3866 in participants with moderate and severe hepatic impairment (HI) compared to that of matched healthy participants. The primary purpose of this study is to understand the effect of HI on the plasma PK of MK-3866 in order to guide dosing recommendations for participants with HI. This study will also evaluate the safety and tolerability of MK-3866 in participants with moderate and severe HI.

Start Date19 Dec 2017

Sponsor / Collaborator

Merck Sharp & Dohme Corp.

NCT03259087

/ CompletedPhase 1

A 2-Part, Open-Label Trial to Evaluate the Pharmacokinetics of MK-3866 Following the Administration of a Single IV Dose to Subjects With Mild, Moderate, and Severe Renal Impairment and End Stage Renal Disease

The purpose of this study is to compare plasma and urine PK parameters of MK-3866 between participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3866 is removed from the plasma by hemodialysis (HD), and evaluate the safety and tolerability of MK-3866 in participants with impaired renal function.

Start Date01 Sep 2017

Sponsor / Collaborator

Merck Sharp & Dohme Corp.

100 Clinical Results associated with MK-3866

Login to view more data

100 Translational Medicine associated with MK-3866

Login to view more data

100 Patents (Medical) associated with MK-3866

Login to view more data

100 Deals associated with MK-3866

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kidney Failure, Chronic	Phase 1	United States	Merck Sharp & Dohme Corp.	01 Sep 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03295266 (3866-006 \| MK-3866-006, CTgov)	Phase 1	Hepatic Insufficiency	9	MK-3866 (Moderate Hepatic Impairment (Panel A))	bbjjvckbna(yqoreuuxdw) = nrdwfxhubu mnjzfrsxqo (bnqnkpnlqd, 7.3) View more	-	13 Nov 2019
				MK-3866 (Severe Hepatic Impairment (Panel B))	bbjjvckbna(yqoreuuxdw) = mlodnqaxhd mnjzfrsxqo (bnqnkpnlqd, 41.4) View more
NCT03259087 (3866-005 \| MK-3866-005, CTgov)	Phase 1	Kidney Failure, Chronic	42	MK-3866 (Part 1: Moderate Renal Impairment)	efoyliwcxe(socftbsarj) = fraddribcq uepjfhtboa (ximbdxzzwp, bhrhwuaiop - cpbtyhvgqq) View more	-	19 Apr 2019
				MK-3866 (Part 1: Severe Renal Impairment)	efoyliwcxe(socftbsarj) = lirxawlmfn uepjfhtboa (ximbdxzzwp, mgcmywulao - xkwsqmykvn) View more